CytomX's Breast Cancer Candidate Meets Primary Goal Of Objective Response Rate

CytomX Therapeutics Inc's  (NASDAQ: CTMX ) Phase 2 study of praluzatamab ravtansine in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A) met its primary efficacy endpoint  of confirmed objective response rate (ORR) of more than 10%. As of the data cutoff on May 13, 47 patients unselected for CD166 expression with advanced ... Full story available on Benzinga.com